chrisvoncsefalvay/vaers-outcomes huggingface dataset:
It was reported that an adult female pt received a Fluzone SV '00-'01 vaccination (lot number not provided) on 20 Dec 2000. Reportedly within ten minutes of receiving vaccination the pt experienced a systemic reaction consisting of throat closing, face swelling and shortness of breath.
Patient reported not being able to move her right arm starting  overnight the night she received the vaccines. She also stated she was vomiting, had fever chills, redness at the injection site. She called an ambulance and went the emergency room where she states she was told she had cellulitis due to either the injection site being contaminated or contamination of the vaccine. She was treated with cephalexin.
31 yo healthy male who was referred to agency for adverse reaction to anthrax vaccine #7 reports severe edema, erythema, tenderness, induration and pruritus onset 1 day after vaccine receipt on 23 AUG. Pain was as high as 4/10. affected function, difficulty lifting his arm, although no weakness. He was seen by clinic and treated with prednisone and BENADRYL. Site is greatly improved, most erythema resolved, minimal pruritus, pain now 1/10, normal ROM.
12/2 got vaccine 12 noon by 5 pm pt felt like had the flu (achy) at 8pm face swelling & numbness took benadryl 25g. Arm is swollen and red as of 12/5
Pretty high fever. 102.2; This spontaneous case was reported by a consumer and describes the occurrence of PYREXIA (Pretty high fever. 102.2) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced PYREXIA (Pretty high fever. 102.2). At the time of the report, PYREXIA (Pretty high fever. 102.2) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Body temperature: 102.2 (High) Pretty high fever. 102.2.         No concomitant medications were reported.  No treatment information was provided.
When attempting to schedule dose #2, was advised by the family that the patient passed away on 3/13/2021.
27aug89 pt vax hepta B. pt ex pain and a stiff neck which lasted 7 days and then resolved.  pt recvd 3rd dose 5 mnths later w/o incident.
This case was reported by a other health professional via sales rep and described the occurrence of vaginal bleeding in a 17-year-old female patient who received BEXSERO. On 5th January 2017, the patient received BEXSERO. On an unknown date, less than a year after receiving BEXSERO, the patient experienced vaginal bleeding. On an unknown date, the outcome of the vaginal bleeding was not reported. It was unknown if the reporter considered the vaginal bleeding to be related to BEXSERO. Additional details were provided as follows: The age at vaccination was not reported. In 2017, the patient experienced vaginal bleeding. The batch number and anatomical location of the vaccine were unknown.
sore arm; fatigue; This is a spontaneous case report received by Pfizer. A non-contactable elderly male consumer (patient, self-reported).   An elderly male patient of an unspecified age received first dose of BNT162B2 (PFIZER-BIONTEC COVID-19 mRNA VACCINE, Solution for injection, lot number and expiry date were not reported), via Intramuscularly, on an unspecified date, as a single dose for COVID-19 immunization and risankizumab (SKYRIZI, unknown formulation) via Subcutaneous, on an unspecified date for moderate to severe chronic plaque psoriasis. The patient's medical history and concomitant medications were not reported. It was unknown if patient was enrolled in a COVID-19 Vaccine Trial. The patient reported that on an unspecified date, he experienced sore arm and fatigue. The patient received unspecified treatment for the events. Outcome of the events was unknown.  No follow-up attempts are possible; information about lot/batch number cannot be obtained.
expired covid19 vaccine was administered.  Had stayed in room temperature in syringe for longer than 6 hours
This spontaneous report was received from a Registered Nurse and refers to multiple unspecified patients of unknown age and gender. No information on patient's concurrent conditions, medical history and concomitant medications was reported. On unknown dates, since approximately 2011 (reported as "over the past 6 years"), the patients were vaccinated with PROQUAD (doses, routes of administration, lot numbers and expiry dates not provided) reconstituted with sterile diluent (manufacturer unknown) (doses, routes of administration, lot numbers and expiry dates not provided). On unknown dates, the patients experienced injection site stinging. No product quality complained was involved. The outcome of the event was unknown. Causality assessment was not specified. This is one of several reports received from the same reporter. Additional information has been requested. Sender's Comments: US-009507513-1705USA008994: US-009507513-1705USA014280: US-009507513-1705USA014281.
Vaccination was a 7:45 am Monday.  On Tuesday at mid morning I started showing an allergic reaction.  Itchy red spots all over head, ears and neck, some on lower part of body.  Swollen lip.  Took two benadryl at 1:45 am Wednesday .  This helped to ease the itching.  Had a headache so on Wednesday morning I took two Tylenol and made a Dr. appt.  Also was weak and faintish on Wednesday when I got up.   Dr's said to keep taking anti-histamines and report to ER if tongue or throat starts to swell.
Nauseous within 3 minutes or receiving shot. Lethargic general feeling of being unwell and severe headache.
20 minutes after receiving vaccine, left-sided neck pain, earache and soreness was reported. No rash or difficulty breathing was recorded. 3/10 pain in the left injection site after 45 minutes. No medications were given and they reported back to work.
Pt vaccinated with DTP minutes later became pale, cool and clammy to touch, visibly shaky, elevated pulse rate, and low blood pressure.  Child placed supine, w/feet elevated above heart level.  Fully recovered within 5 mins.
He received pneumovax, 2nd dose shingrix, and fluarix Tuesday September 15, 2020 in the morning. That evening per Dr's office patient reported to hospital with 104F fever, Shortness of breath, high blood pressure. He was seen at the hospital for 2 hours bloodwork taken, Covid test done (was negative) the hospital discharged him hour per Dr.'s office with diagnosis of Hypertension.
sweats; swellon arm; Headache; fever; nausea; chills; This spontaneous case was reported by an other health care professional and describes the occurrence of HYPERHIDROSIS (sweats), PERIPHERAL SWELLING (swellon arm), HEADACHE (Headache), PYREXIA (fever) and NAUSEA (nausea) in a 39-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 001B21A and 001B21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     The patient's past medical history included Polycystic ovarian syndrome. Concurrent medical conditions included Drug allergy (Allergic to codeine).   On 12-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 11-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 11-Mar-2021, the patient experienced HYPERHIDROSIS (sweats), PERIPHERAL SWELLING (swellon arm), HEADACHE (Headache), PYREXIA (fever), NAUSEA (nausea) and CHILLS (chills). At the time of the report, HYPERHIDROSIS (sweats), PERIPHERAL SWELLING (swellon arm), HEADACHE (Headache), PYREXIA (fever), NAUSEA (nausea) and CHILLS (chills) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Concomitant products were not provided. Treatment products were not provided.
Initial report was received from a healthcare professional on 03 May 2013. A 44-year-old female patient had received an intramuscular injection in the right deltoid of ADACEL, lot number C4365AA, on 30 April 2013. The next day, on 01 May 2013, the patient experienced soreness of the arm, swelling of the injection area and under the arm. Two days later, on 03 May 2013, the patient reported very painful arm with redness around the injection site and axilla swelling. The patient was directed to go to the hospital emergency room for evaluation and treatment. A doppler sonogram documented a small deep vein thrombosis (DVT) of right brachial complex. The patient was hospitalized and is being treated with anticoagulant. The patient had no illness at the time of vaccination and allergies to penicillin, clindamycin, tetracycline and NAPROSYN. Outcome was not recovered. Documents held by sender: None.
Tiredness, Sore arm, large armpit swelling, extreme tenderness, swollen lymph nodes in armpit on the same side as vaccine injection. Tiredness and sore arm started within 24 hours following injection.  Swelling under armpit of lymph nodes and associated pain occurred around 05/28/2021 and is still present.
Patient here for follow up left arm cellulitis following immunization with PREVNAR 13. Patient has tolerated KEFLEX and arm is feeling much better. No further pain. Redness has almost completely faded. Denies fever, chills, nausea, headache, numbness or tingling.
The patient received routine immunizations at his well baby visit on 4/6/12; a few hours later he was noted to be sleeping longer than his usual nap. Mom found him difficult to arouse, limp and with his eyes "rolled back". He transported to ER then hosp. for 2 days and was normal by exam and monitoring. His LP, septic w/o cultures. Chemistry panel and toxic screen were normal. An out-pt. EEG was normal. Mild pulmonic stenosis. Hemodynamically stable, no arrythmia, atrial septal defect.
Expired vaccine used; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Expired vaccine used) in a 60-year-old patient of an unknown gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 031B21A) for COVID-19 vaccination.     No Medical History information was reported.    On 12-Nov-2021, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 12-Nov-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (Expired vaccine used). On 12-Nov-2021, EXPIRED PRODUCT ADMINISTERED (Expired vaccine used) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications were reported. No treatment information was provided
Site: Bruising at Injection Site-Medium, Site: Pain at Injection Site-Medium, Systemic: Joint Pain-Severe
Five days post vaccine patient developed macular, papular, vesicular rash over entire body. mom reports started on the patients face. mom also reports fever with the onset of rash.
Information has been received from a physician concerning an immunocompromised patient with cerebral palsy who on 04/11/01, was vaccinated with Varicella virus vaccine live. On 04/15/01, the patient developed a severe case of chicken pox. On the same date, the patient was hospitalized for a skin infection which was considered possibly due to the chicken pox. The physician reported that the patient had no prior exposure to wild type varicella and that he did not know the nature of the skin infection. In follow-up, the physician reported that he did not have much additional information to report but was in the process of trying to gather additional information. In addition, the physician stated that he believed that the patient had not had a recent varicella exposure, was not immunocompromised and had recovered but will attempt to confirm this information. Additional information has been requested. Follow up information has been received from a physician who reports the patient was diagnosed with cellulitis and secondary infected chicken pox and had subsequently recovered as of 04/30/2001. It was reported that the child had a persistent fever with his chicken pox. When admitted to the hospital he was treated with Kefzol. At the time of discharge the pt did have some active pox, but he was afebrile and his appetite had returned. He was given Duricef at discharge to continue for 1 week. No further information is expected.
lightheadedness, tachycardia, hypertension (190/110), transient
weak, fever, throwing up, diarrhea, shortness of breath, low oxygen (79)
Mostly nonverbal pt developed temp 100-102 evening following vaccine through following day, and on day 3 had significant chest pain warranting 911 call and ED visit.  Labs were significant for leukocytosis (WBC 19.8) and CXR w R hilar pneumonia.  Troponin level was normal.  He has improved on ABX.
Low lying placenta; Vaccine exposure during pregnancy; This is an observational study case, initially received on 01-Nov-2019, concerning a 36-year-old pregnant, female subject of body weight 147.5 lbs, height 63 inches and body mass index (BMI) 26.1 enrolled in, a prospective observational safety study. The subject's partner age was 37.  The subject's obstetrical history noted that the subject had one previous full-term, live birth pregnancy with no birth defects. The subject had no history of offspring with major congenital malformation (MCM). Also, the subject had no maternal or paternal history with MCM. The subject did not use tobacco, alcohol or illicit drugs during pregnancy.   The subject's last menstrual period (LMP) date was 23-Apr-2019. The subject's estimated date of delivery (EDD) and corrected estimated date of delivery (CEDD) were reported as 28-Jan-2020. The type of pregnancy was singleton.   The subject's current medical conditions included hematochezia, interstitial cystitis, nausea, vitamin D deficiency and high body mass index. The subject's risk factor included advanced maternal age at 36 years. Concomitant medications included Uribel (hyoscyamine, methenamine, methylthioninium, phenyl salicylate, and phosphoric acid) for interstitial cystitis, cholecalciferol for vitamin D deficiency, Bonjesta (doxylamine succinate, pyridoxine hydrochloride) for nausea and Prenate Mini (folic acid, iron, minerals NOS and vitamins NOS) as prenatals.  On 03-Sep-2019, the subject underwent ultrasound and no MCM was noted.  On 30-Sep-2019, the subject underwent ultrasound and no MCM was noted.  On 24-Oct-2018, at approximately 26 weeks of gestation, the subject was administered Afluria QIV [influenza vaccine, subunit influenza virus vaccine polyvalent, cell cultured derived, batch number: P100126099, dose, route of administration, anatomical location and expiration date: not reported] (explicitly coded as ''Vaccine exposure during pregnancy'') for an influenza immunisation.   On the same day, the subject underwent ultrasound and no MCM was noted.  On an unknown date, the subject's pregnancy status was collected, and it was noted that the subject had a low-lying placenta as a pregnancy complication. No further details were provided.  At the time of initial reporting, the outcome of the event was not reported.   The case was assessed as serious.   The reporter did not provide causality assessment to Afluria Quadrivalent.  Company comment: Placenta praevia was diagnosed on an unknown date after vaccination with Afluria. Based on the available information causal involvement of Afluria is unlikely, however cannot be excluded, therefore this event is assessed as related to the suspect vaccine. Exposure during pregnancy is unrelated to the product per company's conventions.; Sender's Comments: Placenta praevia was diagnosed on an unknown date after vaccination with Afluria. Based on the available information causal involvement of Afluria is unlikely, however cannot be excluded, therefore this event is assessed as related to the suspect vaccine. Exposure during pregnancy is unrelated to the product per company's conventions.
11/3/22 2:00 AM Severe cough for 2 hours (suppressed with Dextromethorphan 11/3/22 4:00 AM Severe chills and violent shaking for three hours 11/3/22 6:00 AM Fever 96.5 (yes, low.  Common for me) for two hours (suppressed with Tylenol) 11/3/22 9:00 AM Fever 99.4 for most of day 11/3/22 5:00 PM Fever 100.4 for two hours so far, and still going (Tylenol not helping)
This is an instance of breakthrough COVID-19 disease after which death occurred. The individual was vaccinated with the Janssen product on 05/06/2021. They tested positive via antigen test on 09/16/2021 at the nursing home at which they were a resident. They presented to emergency department on 09/24/2021 with primary complaint of low oxygen saturation. The individual reported no symptoms such as shortness of breath, etc. The individual was sent to emergency dept by their primary care provider, who had noted the low oxygen saturation. The individual's oxygen saturation was normal when it was checked in the emergency department. I see no indication the individual was admitted to hospital. The individual died on 09/29/2021, although some clinical notes have the death date as 10/01/2021. The death certificate has 09/29/2021 as date of death.
24 hours post vaccine, the patient experienced lightheaded, faint, nausea along with a drop in BP (60/systolic)
Systemic: Numbness (specify: facial area, extremities)-Mild, Systemic: Tingling (specify: facial area, extemities)-Mild, Additional Details: Patient reported numbness and tingling of left leg, the day after administration of tdap and TB skin test. She stated it lasted for a few hours and then it went away. I saw patient on 2/10/23 to have her TB read, and patient states she feels better and did not go to ER or got any medical attention. TB was negative and normal.
10-15 min duration of shaking all over, labored breathing, color of lips/hands/feet dark & blue, fever 102-103.
On 12/15/2021 this patient was given a Covid-19 Pfizer booster before the six month time period. We have attempted to contact the patient above via phone call and they did not answer and did not have a voicemail box. has been notified as well as the report for vaers.
Patient called me this morning to advise me that he experienced heart attack symptoms 45 minutes after receiving his first does of Moderna and self-admitted to the ER. ER confirmed that he had experienced a heart attack and had one clogged artery. He asked about reporting and I told him I would report to VAERS on his behalf as his doctor and the hospital refused to do so. He asked whether or not I would suggest he receive his second dose and I suggested that he speak with his cardiologist and doctor to make that decision. I also informed him that he can search VAERS to see what the other reactions may have been that were reported. Patient indicated that he felt well and has recovered.
This case involves a patient (unknown demographic) who was home sick for at least a week (illness) after receiving INFLUENZA VACCINE. The patient had no medical history, concomitant disease or risk factor. The patient medical treatment(s), vaccination(s) and family history were not provided. On an unknown date, the patient received a dose of suspect INFLUENZA VACCINE produced by unknown manufacturer [lot number and expiry date not reported] via unknown route in unknown administration site for prophylactic vaccination. On an unknown date the patient developed a non-serious was home sick for at least a week (illness) (unknown latency) following the administration of INFLUENZA VACCINE. It was reported "Haven't gotten one in over 35 years and I don't get the flu. When I did get the shot I was home sick for at least a week." There were no lab data/results available. It was unknown if the patient experienced any additional symptoms/event. It was not reported if the patient received a corrective treatment for the event. At time of reporting, the outcome was unknown for the reported event. There will be no information on the batch number for this case.
About 5 minutes after the vaccine administration patient reported her arm was itchy and she was feeling warm. Patient had a rash on her arm that spread to her neck and chest. She was given 50mg diphenhydramine and then monitored for an hour after vaccination. Her rash slowly improved over the hour.
asthma symptoms; Initial information was received on 20-Jan-2021 regarding an unsolicited valid non-serious case from a consumer or non-healthcare professional [under reference number: US-SA-SAC20210128000259].  This case involves an adult patient who experienced asthma symptoms (asthma), while the patient received INFLUENZA VACCINE.  Medical history, medical treatment, vaccination, concomitant medication and family history were not provided. It is unknown if the patient had any concomitant disease or risk factor.  On an unknown date, the patient received a dose of suspect INFLUENZA VACCINE produced by unknown manufacturer [lot number and expiry date not reported] via an unknown route at an unknown administration site for prophylactic vaccination.  On an unknown date, the patient developed a non-serious asthma symptoms (asthma) unknown latency following the administration of INFLUENZA VACCINE.  It is unknown if the patient experienced any additional symptoms/events.  Relevant laboratory test results included: On an unknown date SARS-CoV-2 test [Covid test] was done.  It is unknown if there were lab data/results available.  It was not reported if the patient received a corrective treatment.  At the time of reporting, the event outcome was unknown.  There will be no information on batch number of this case.
Fever to 101-102. (R) arm erythema and severe pain out of proportion to exam - R/O invasive strep.  4/27/09 Received hospital medical records of 1/7-1/8/2009. FINAL DX: right arm with vaccine injection cellulitis Records reveal patient experienced pain in right upper arm since evening of vaccination.  Next day developed fever & RUE swelling & erythema with decreased right elbow ROM.  Erythema continued to enlarge w/warmth & increased pain & unable to fully extend elbow.  Tx w/oral antibiotics but condition did not improve.  PCP exam suggested possible invasive strep & pt hospitalized for IV antibiotics.  Remained stable, site improved & d/c to home on continued oral antibiotics.
46 y/o male with prior hx of vaccine related myocarditis following SPV in 2005 developed chest tightness, SOB, tachycardia 4-5 days after his second Moderna vaccine. Not seen by a medical provider until 3/25/21. EKG showed ST seg elevation V1-5. ECHO normal, CRP/ESR normal. No trop drawn.  Continues with mild SOB with exertion. Placed on a beta blocker for tacycardia.
pt recv vax 27JUL98 & 30JUL woke up during noc w/fever of 101.6 axillary;no other specific complaints-mom gave APAP but fever cont through next day;
Severe pain, loss of range of motion. Shoulder treatments and eventual shoulder surgery (1-15-16) bursitis inflammation. Six months later still pain and limited range of motion.
This spontaneous report as received from a pharmacist via a company representative refers to a 74 year old male patient. In approximately October 2017 (reported as October or November 2017, "after the hurricane"), the patient was vaccinated with PNEUMOVAX 23 (lot number, dose, route and site of administration were not reported) for prophylaxis. In 2017, the patient experienced redness, but not in the vaccination area. The redness was closer to the elbow. The patient self-treated with ice. The outcome of redness was reported as resolved in approximately 2017. The relatedness between the event and PNEUMOVAX 23 was not reported. This is one of several reports received from the same reporter.; Sender's Comments: US-009507513-1712USA009288: